New CardioQ. trial

Deltex Medical Group PLC
18 September 2006


                             Deltex Medical Group plc

             New CardioQ(TM) trial in paediatric intensive care units

18 September 2006 Deltex Medical Group plc ('Deltex Medical' or the 'Company'),
the UK's leading haemodynamic monitoring company, today announces the
commencement of a clinical trial of the paediatric version of its CardioQ
oesophageal Doppler monitor (ODM).

Doctors in the paediatric intensive care unit (PICU) of a major UK children's
hospital are undertaking an extensive trial into the efficacy of the CardioQ as
a cardiac output monitor in babies and small children.

The rationale behind the study is that children who are critically ill on a
ventilator in intensive care require detailed monitoring of their cardiac output
status in order to optimise controlled administration of fluid and drugs. The
Directors are not aware of any method of cardiac output monitoring that has been
shown to improve patient outcomes in PICU; the Directors further believe that
ODM is the only minimally invasive cardiac output monitoring technology which
can be used on babies and small children which has also been shown to improve
outcomes in adults post-operatively in intensive care in randomised controlled
clinical trials.  With a positive outcome, the doctors leading this study intend
to go on to conduct a full randomised controlled clinical trial designed to
demonstrate improved outcomes in PICU using the CardioQ to improve haemodynamic
management post-operatively.

Deltex Medical's chief executive, Andy Hill, commented:

'The CardioQ is already known to be considerably safer than the more invasive
alternatives and we expect that positive results from this trial will give us a
significant long term competitive advantage in the niche PICU cardiac output
monitoring market. Combined with the substantial adult intensive care and the
intra-operative markets, the potential for CardioQ continues to grow'.

For further information, please contact:-

Deltex Medical Group plc                         01243 774 837
Nigel Keen, Chairman                             [e-mail]
Andy Hill, Chief Executive                       [e-mail]
Ewan Phillips, Finance Director                  [e-mail]

Gavin Anderson & Company                         0207 554 1400
Deborah Walter                                   [e-mail]
Marie Cairney                                    [e-mail]
Jodie Reilly                                     [e-mail]

Charles Stanley Securities                       020 7149 6457
Philip Davies                                    [e-mail]


Notes for Editors

Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs. This causes medical
complications including peripheral and major organ failure which can lead to
death. Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself. Using fluids and drugs, guided by the CardioQ, to optimise the amount of
circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.

There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-

  • Validated the results of the Monitor against known standards for measuring
    cardiac output, demonstrating that the technology works

  • Proved that the CardioQ works in a wide range of surgical procedures

  • Demonstrated that the Company's technology provides significant health and
    economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.


                      This information is provided by RNS
            The company news service from the London Stock Exchange